Study of Optimal Treatment Plan in Hypertensives With Anti-AT1-Receptor Autoantibody
Status:
Unknown status
Trial end date:
2006-12-01
Target enrollment:
Participant gender:
Summary
The autoantibodies against AT1 receptor (ATR-AA), behaving like an agonist were detected in
patients with hypertension. ATR-AA which can blocked by ARB may play a role in the
pathogenesis of hypertension. The present study is to explore whether AT1 receptor blocker
has superior anti-hypertensive effect in patients with positive ATR-AA hypertension. Patients
with 2 grade hypertension were recruited and ATR-AA was assayed by ELISA. A study was carried
out and the efficacy of anti-hypertension was compared between candesartan cilexetil and ACE
inhibitor imidapril.